<div id="readability-page-1"><p>In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Beam Therapeutics, with a price target of <span id="expert-recommendation-target">$35.00</span>. The company’s shares closed yesterday at $27.77.</p><h3>Claim 70% Off TipRanks This Holiday Season</h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Kasimov covers the Healthcare sector, focusing on stocks such as Moderna, Neurocrine, and Vertex Pharmaceuticals. According to TipRanks, Kasimov has an average return of <span>16.2%</span> and a 55.19% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beam Therapeutics with a $43.00 average price target, implying a 54.84% upside from current levels. In a report released on December 9, Bank of America Securities also maintained a Buy rating on the stock with a $43.00 price target.</p></div>

BEAM

<p>Evercore ISI's Cory Kasimov maintains a Buy rating on Beam Therapeutics with a $35 price target. Shares closed at $27.77. Analysts suggest a Strong Buy consensus with a $43 average price target, indicating a 54.84% upside. Bank of America Securities also maintains a Buy rating with a $43 target.</p>

Beam Therapeutics (BEAM) Receives a Buy from Evercore ISI